Latest filings (excl ownership)
ARS
2024 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
10-K
2023 FY
Annual report
8 Mar 24
8-K
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
8 Mar 24
8-K
Other Events
6 Dec 23
EFFECT
Notice of effectiveness
16 Nov 23
424B5
Prospectus supplement for primary offering
15 Nov 23
CORRESP
Correspondence with SEC
13 Nov 23
UPLOAD
Letter from SEC
8 Nov 23
S-3
Shelf registration
3 Nov 23
10-Q
2023 Q3
Quarterly report
3 Nov 23
8-K
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
3 Nov 23
8-K
Ligand will receive 13% of all soticlestat royalties and milestone payments owed to Ovid
18 Oct 23
8-K
Dawn of the neurotherapeutics era Dr. Jeremy Levin CEO & Chairman
2 Oct 23
10-Q
2023 Q2
Quarterly report
4 Aug 23
8-K
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
4 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
S-8
Registration of securities for employees
5 May 23
10-Q
2023 Q1
Quarterly report
5 May 23
8-K
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
5 May 23
8-K
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
1 May 23
8-K
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
27 Apr 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
10-K
2022 FY
Annual report
13 Mar 23
8-K
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
13 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
8 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
9 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
10 Jun 22
8-K
Other Events
11 May 22
10-Q
2022 Q1
Quarterly report
10 May 22
8-K
Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
10 May 22
DEFA14A
Additional proxy soliciting materials
2 May 22
DEF 14A
Definitive proxy
29 Apr 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Mar 22
Latest ownership filings
4
JEREMY M LEVIN
20 Mar 24
4
Jason Tardio
26 Feb 24
4
Jeffrey A Rona
26 Feb 24
4
Robert Michael Poole
26 Feb 24
4
Thomas Michael Perone
26 Feb 24
4
JEREMY M LEVIN
26 Feb 24
4
Bart Friedman
26 Feb 24
4
Kevin Joseph Fitzgerald
26 Feb 24
4
Barbara Gayle Duncan
26 Feb 24
4
Karen Bernstein
26 Feb 24
SC 13G/A
LEVIN JEREMY M
14 Feb 24
4/A
JEREMY M LEVIN
14 Feb 24
SC 13G/A
Madison Avenue Partners, LP
14 Feb 24
SC 13G/A
Rubric Capital Management LP
12 Feb 24
SC 13G
BlackRock Inc.
29 Jan 24
4
JEREMY M LEVIN
6 Dec 23
SC 13G
Madison Avenue Partners, LP
31 Jul 23
4
Jason Tardio
27 Feb 23
4
Jeffrey A Rona
27 Feb 23
4
Robert Michael Poole
27 Feb 23
4
Thomas Michael Perone
27 Feb 23
4
JEREMY M LEVIN
27 Feb 23
4
Bart Friedman
27 Feb 23
4
Kevin Joseph Fitzgerald
27 Feb 23
4
Barbara Gayle Duncan
27 Feb 23
4
Karen Bernstein
27 Feb 23
SC 13G/A
LEVIN JEREMY M
14 Feb 23
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 23
SC 13G/A
Stonepine Capital Management, LLC
13 Feb 23
SC 13G
Rubric Capital Management LP
10 Feb 23
SC 13G/A
EcoR1 Capital, LLC
10 Feb 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
SC 13G/A
TAKEDA PHARMACEUTICAL CO LTD
3 Feb 23
SC 13G/A
TAKEDA PHARMACEUTICAL CO LTD
3 Feb 23
4
Jason Tardio
14 Sep 22
4
Change in insider ownership
6 Jul 22
4
Bart Friedman
12 Apr 22
4
Jason Tardio
12 Apr 22
4
JEREMY M LEVIN
12 Apr 22
4
Jeffrey A Rona
12 Apr 22